Details for Patent: 6,521,212

Title:	Method for treating peripheral vascular disease by administering benzindene prostaglandins by inhalation
Abstract:	A method of delivering benzindene prostaglandins to a patient by inhalation is discussed. A benzindene prostaglandin known as UT-15 has unexpectedly superior results when administered by inhalation compared to parenterally administered UT-15 in sheep with induced pulmonary hypertension.
Inventor(s):	Cloutier; Gilles (Chapel Hill, NC), Crow; James (Chapel Hill, NC), Wade; Michael (Chapel Hill, NC), Parker; Richard E. (Spring Hill, TN), Loyd; James E. (Nashville, TN)
Assignee:	United Therapeutics Corporation (Silver Spring, MD)
Filing Date:	Mar 15, 2000
Application Number:	09/525,471
Claims:	1. A method of treating peripheral vascular disease comprising administering to a mammal in need thereof by inhalation a formulation comprising a therapeutically effective amount of a benzindene prostaglandin. 2. The method of claim 1, wherein said benzindene prostaglandin is inhaled in an aerosolized form. 3. The method of claim 2, wherein said benzindene prostaglandin is UT-15. 4. The method of claim 3, wherein said aerosolized form comprises droplets less than 10 micrometers in diameter, said droplets comprising said UT-15 in a suitable pharmacologically-acceptable liquid carrier. 5. The method of claim 1, wherein the mammal is a human. 6. A method for treating pulmonary hypertension in a mammal comprising delivering to said mammal an effective amount of UT-15 or its pharmaceutically acceptable salt or ester by inhalation. 7. The method of claim 6, wherein said UT-15 is inhaled in an aerosolized form. 8. The method of claim 7, wherein said aerosolized form comprises droplets less than 10 micrometers in diameter, said droplets comprising said compound in a suitable pharmacologically-acceptable liquid carrier. 9. The method of claim 6, wherein said UT-15 is inhaled in powder form comprising particles less than 10 micrometers in diameter. 10. The method of claim 1, wherein the formulation comprises a sustained release form of a benzindene prostalandn. 11. The method of claim 6, wherein said UT-15 is a sustained release form. 12. The method of claim 1, wherein said aerosolized administration of benzindene prostaglandin has no effect on heart rate.